At Rhythm Biosciences, we’re dedicated to transforming patient outcomes through disease risk assessment, earlier disease detection and diagnosis and treatment decision support. Discover stories, news, and breakthroughs showcasing our innovative cancer detection technologies and their real-world impact.
For more information or to arrange an interview, please contact admin@rhythmbio.com
Rhythm Biosciences teams up with US-based datma to accelerate genomic diagnostic innovation
December 2025 – Rhythm Biosciences has inked an exploratory collaboration with US-based datma to evaluate how its datma.FED federated data platform could support and accelerate commercialisation of Rhythm’s genomic-integrated cancer risk prediction tools.
Read the full Stockhead article here:
Rhythm Biosciences teams up with US-based datma to accelerate genomic diagnostic innovation – Stockhead
Rhythm’s ColoSTAT delivers consistent cancer detection across ages and genders
October 2025 – Rhythm’s ColoSTAT demonstrates conclusive performance in patients aged 45 to 80 diagnosed with colorectal cancer.
ColoSTAT performance consistent across both males and females.
Data indicates potentially suitable for early onset cancer in patients under 50.
Further analysis of Rhythm Biosciences’ final validated ColoSTAT blood test for colorectal cancer continues to show strong and consistent performance across different age groups and gender.
Read the full Stockhead article here:
Rhythm’s ColoSTAT delivers consistent cancer detection across ages and genders – Stockhead
Rhythm Biosciences Featured in 'ASX Companies on Front Line of Advancing Breast Cancer Care'
A recent feature article on Stockhead highlights Rhythm Biosciences’ role as a leader in innovative cancer diagnostics through the geneType Breast Cancer Risk Assessment Test.
The article focuses on how Rhythm is helping to transform early detection by offering a comprehensive, proactive approach that complements existing screening pathways. The geneType platform provides significant value by integrating clinical data, family history, and cutting-edge polygenic risk scores to deliver personalised, actionable disease risk insights. This empowers women and their healthcare providers to make informed decisions about preventative care and screening schedules.
Discover how this innovative predictive diagnostic platform is advancing personalised medicine and transforming outcomes for breast cancer patients.
Read the full Stockhead article here:
ASX companies on front line of advancing breast cancer care – Stockhead
Media coverage - Business News Australia
December 2024 – Rhythm announced it was acquiring the geneType™ business and assets to create a diversified oncology business with significant growth potential. The geneType™ business is a world leader in genetic-integrated risk assessment that offers population level predictive risk testing for a range of cancers and other serious and common diseases. The ability to quantify risk of disease using polygenic risk scores and clinical factors supports Rhythm’s goal of detecting disease earlier in a uniquely personal manner.
Read the news coverage here: https://tinyurl.com/mrs4chw2
Talking quality assurance with Gary Goh
Media coverage - Stockhead
December 2024 – Rhythm announced to the market that we had attained all key milestones for 2024. Read the subsequent media coverage in Stockhead here: https://tinyurl.com/y7pbbr5r
Half year investor program
Extraordinary General Meeting 31 March 2025
Media coverage - Small Caps
October 2024 – We announced to the market that preliminary testing of 200 patient serum samples using the new multiplex Alpha antibody kit revealed superior analytical results compared to tests performed on the first-generation product. Read more here: https://tinyurl.com/5est5upc
Interview - MTPConnect Podcast
157. Team Australia: Doing Business at BIO 2023 in Boston
In June 2023 Rhythm Biosciences Chief Commercial Officer Elena Deak attended BIO in Boston where she spoke with Caroline Duell from MTPConnect.
“Back in June, MTPConnect joined the Australian delegation at BIO in Boston and organised several activities to showcase Australia’s fast-growing life sciences sector to the international biotech industry.
In part one of this BIO episode, host Caroline Duell heads to the Australian Pavilion at the Boston Convention Centre to catch up with Australian companies, entrepreneurs and researchers looking to do business at BIO and drive collaborations, partnerships and investments.”
For more on MTP Connect and the podcast visit: https://www.mtpconnect.org.au/mtpconnectpodcast
Elena’s Interview starts at 19:05. To listen, click play:
